Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma

CONCLUSIONS: In this first randomized trial in patients with ACC, axitinib significantly increased the 6-month PFS rate as compared to observation. (ClinicalTrials.gov number, NCT02859012).PMID:34315722 | DOI:10.1158/1078-0432.CCR-21-1061

Source: Clinical Cancer Research - July 28, 2021 Category: Cancer & Oncology Authors: Eun Joo Kang Myung-Ju Ahn Chan-Young Ock Keun-Wook Lee Jung Hye Kwon Yaewon Yang Yoon Hee Choi Min Kyoung Kim Jun Ho Ji Tak Yun Byung-Ho Nam Sung-Bae Kim Bhumsuk Keam Source Type: research